People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Relay Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.0M | $253.2M | 2024 |
Linda A. Hill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Linda A. Hill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alexis A. Borisy | 1 | 3 |
| Douglas S. Ingram | 1 | 3 |
| Thomas A. Catinazzo | 1 | 1 |
| Peter A. Rahmer | 1 | 1 |
| Sekar S. Kathiresan | 1 | 1 |
| Sanjiv K. Patel | 1 | 1 |
| Mark S. Murcko | 1 | 1 |
| Laura S. Shawver | 1 | 1 |
| Brian K. Adams | 1 | 1 |
| Jami S. Rubin | 1 | 1 |
| Donald A. Bergstrom | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.